# OligoRARE (NCT04498767)

> Stereotactic Body Radiotherapy in Patients With Rare Oligometastatic Cancers (OligoRARE)

No report yet. It can be ordered.

- Drugs tested: none (the trial tests a strategy, not a drug)
- Indication: rare oligometastatic cancers

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04498767
- Phase: NA
- Status: RECRUITING
- Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
- Conditions: Gynecologic Cancer; Skin Cancer; Head and Neck Cancer; Sarcoma; Renal Cancer; Bladder Cancer; Upper Urinary Tract Carcinoma; Pancreatic Cancer; Hepatobiliary Cancer; Gastric Cancer; Small Bowel Cancer; Esophageal Cancer; Melanoma; Colon Cancer; Oligometastasis
- Interventions: Stereotactic body radiotherapy; Palliative RT
- Enrollment: 200
- Primary outcome: Overall survival

## Indexed commentary on OligoRARE so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 46 posts on X
- 2 YouTube videos
- 1 podcast episode

## Order

Deep, $1,950 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=oligorare-nct04498767

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04498767", "email": "<work email>"}; the inbox owner confirms by the emailed link.